Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1030 of 6351
-
New drug combo aims to shrink endometrial tumors
Disease control OngoingThis study will compare the effects of treatment with nivolumab alone versus those of nivolumab plus the experimental drug BMS-986205. Adding BMS-986208 to nivolumab could shrink the cancer or prevent it from returning, but it could also cause side effects.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New combo aims to boost survival in older AML patients
Disease control OngoingRandomized phase III, multicentre, open label clinical trial to compare pevonedistat in combination with azacytidine versus azacytidine alone, which can be considered a standard of care for patients with newly diagnosed acute myeloid leukemia not eligible for intensive chemothera…
Phase 3 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a home sleep test unlock better dementia care?
Diagnosis Recruiting nowObstructive sleep apnea (OSA), which causes abnormal pauses in breathing during sleep, is common in patients with vascular cognitive impairment (VCI) and Alzheimer's disease (AD), and exacerbates the cognitive deficits seen in these conditions. OSA is typically treated with conti…
Sponsor: Sunnybrook Health Sciences Centre • Aim: Diagnosis
Last updated Aug 22, 2026 00:00 UTC
-
Gut reroute surgery shows promise for diabetes control
Disease control OngoingStudy will monitor changes in HbA1c for subjects in Intervention arm vs control arm.
Sponsor: GI Windows, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Off-the-Shelf CAR t cells take on Hard-to-Treat myeloma
Disease control CompletedThe purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/…
Phase 1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for rare ovarian cancer: could hormone therapy replace chemo?
Disease control OngoingThis phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made …
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug shows promise in slowing advanced breast cancer with ESR1 mutation
Disease control CompletedThis is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease …
Phase 2 • Sponsor: Sermonix Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can a milk sugar tame IBD symptoms?
Disease control CompletedRandomized, placebo-controlled dose-ranging study of 2'-FL in IBD, Crohn's Disease (CD) and ulcerative colitis (UC). The overarching hypothesis is that 2'-FL supplementation in IBD will be safe and well tolerated, while increasing fecal Bifidobacterium abundance and butyrate in a…
Phase 1/2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could your own immune cells fight liver cancer? new trial aims to find out
Disease control Recruiting nowThis early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in combination with immune checkpoint inhibition (with bevacizumab and atezolizumab or druvalumab) in treating patients liver cancer that cannot be removed by surgery (unr…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo shows promise for resistant lung cancer in early trial
Disease control CompletedThis study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-s…
Phase 2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Chagas drug shows promise for kids in landmark trial
Disease control OngoingThis study evaluate the efficacy and safety of benznidazole in the treatment of chronic indeterminate Chagas disease in children. All subjects will receive benznidazole and results will be compared to historically to a placebo arm.
Phase 3 • Sponsor: Insud Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Shorter chemo before transplant may cut severe side effects for blood cancer patients
Disease control OngoingThe purpose of this study is to see if a condensed version of the chemotherapy regimen busulfan, melphalan, fludarabine (bu/mel/flu) and the drug antithymocyte globulin (ATG-also referred to as rATG or thymoglobulin) can have the same or fewer number of severe side effects in peo…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThe purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients wi…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Engineered immune cells take aim at rare blood cancer
Disease control Recruiting nowThis is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells will be genetically modified in …
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New heart valve offers hope for High-Risk patients
Disease control OngoingThe purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30…
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New daily pill shows promise in controlling leukemia
Disease control CompletedThis is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts:…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Hearts with hepatitis c: a new hope for transplant patients?
Disease control Recruiting nowIn this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.
Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug cocktail aims to halt smoldering myeloma before it strikes
Disease control Recruiting nowThis phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor ce…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a drug combo stop AML from coming back?
Disease control OngoingThis phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Talking it out: could Village-Led chats curb youth suicide?
Prevention CompletedThis intervention study measures the outcomes of the PC CARES (Promoting Community Conversations about Research to End Suicide) project implemented in remote rural Alaskan villages. Researchers worked with local service providers and other partners to recruit facilitators who wer…
Sponsor: University of Michigan • Aim: Prevention
Last updated Aug 21, 2026 00:00 UTC